Details for New Drug Application (NDA): 207695
NDA 207695 describes EUCRISA, which is a drug marketed by Anacor Pharms Inc and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the EUCRISA profile page.
The generic ingredient in EUCRISA is crisaborole. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the crisaborole profile page.
The generic ingredient in EUCRISA is crisaborole. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the crisaborole profile page.
Summary for 207695
| Tradename: | EUCRISA |
| Applicant: | Anacor Pharms Inc |
| Ingredient: | crisaborole |
| Patents: | 4 |
Pharmacology for NDA: 207695
| Mechanism of Action | Phosphodiesterase 4 Inhibitors |
Suppliers and Packaging for NDA: 207695
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695 | NDA | Pfizer Laboratories Div Pfizer Inc | 55724-211 | 55724-211-11 | 1 TUBE in 1 CARTON (55724-211-11) / 100 g in 1 TUBE |
| EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695 | NDA | Pfizer Laboratories Div Pfizer Inc | 55724-211 | 55724-211-21 | 1 TUBE in 1 CARTON (55724-211-21) / 60 g in 1 TUBE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | OINTMENT;TOPICAL | Strength | 2% | ||||
| Approval Date: | Dec 14, 2016 | TE: | AB | RLD: | Yes | ||||
| Regulatory Exclusivity Expiration: | Apr 3, 2026 | ||||||||
| Regulatory Exclusivity Use: | ADDITION OF A ONCE DAILY DOSING REGIMEN | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Dec 29, 2029 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
| Patent: | ⤷ Start Trial | Patent Expiration: | Jul 20, 2030 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Complete Access Available with Subscription
